Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora’s former diagnostics business.
“This represents continued progress in monetizing our legacy assets,” said Eric d’Esparbes, Chief Financial Officer of Biora Therapeutics. “This transaction provides incremental non-dilutive funding to advance our therapeutics platforms, while enabling the assets to be leveraged for important diagnostic applications.”
Biora Therapeutics will receive a one-time payment for the sale of assets including rights to certain antibody sequences. Specific terms of the agreement were not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.